They'll serve different niches: CagriSema Will Dominate: Patients familiar with Wegovy brand Those wanting proven semaglutide component People with type 2 diabetes (strong REIMAGINE data) Earlier availability (mid-2027) Retatrutide Will Dominate: Patients needing maximum weight loss (BMI 40) Those with multiple complications (OA + OSA + obesity) People who failed CagriSema Willingness to wait for highest efficacy Tirzepatide (Zepbound) Will Remain Relevant: Already available NOW Proven safety with 22.5% weight loss Lower cost than either new option Established insurance coverage The High-Dose CagriSema Wildcard Novo Nordisk announced plans for CagriSema 2.4mg/7.2mg trials starting late 2026tripling the cagrilintide dose
Renal Impairment: In patients treated with GLP-1 receptor agonists, including Saxenda , there have been reports of acute renal failure and worsening of chronic renal failure, usually in association with nausea, vomiting, diarrhea, or dehydration, which may sometimes require hemodialysis
Barbieri RL, Ehrmann DA
Dosing runs daily or weekly depending on the compound, with weekly cadence common in this part of the class
- Requires shaking before use due to the dual-layer formulation
Regulatory frameworks, such as the European Food Safety Authority (EFSA) guidelines, are also shaping the market by ensuring product safety and efficacy, thus boosting consumer confidence
